CL2017001289A1 - Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). - Google Patents

Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).

Info

Publication number
CL2017001289A1
CL2017001289A1 CL2017001289A CL2017001289A CL2017001289A1 CL 2017001289 A1 CL2017001289 A1 CL 2017001289A1 CL 2017001289 A CL2017001289 A CL 2017001289A CL 2017001289 A CL2017001289 A CL 2017001289A CL 2017001289 A1 CL2017001289 A1 CL 2017001289A1
Authority
CL
Chile
Prior art keywords
compositions
treatment
fxr
modulation
fused bicyclic
Prior art date
Application number
CL2017001289A
Other languages
English (en)
Spanish (es)
Inventor
Benjamin Anthony Pratt
Raju Mohan
Original Assignee
Akarna Therapeutics Ltd
Benjamin Anthony Pratt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd, Benjamin Anthony Pratt filed Critical Akarna Therapeutics Ltd
Publication of CL2017001289A1 publication Critical patent/CL2017001289A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2017001289A 2014-11-21 2017-05-19 Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). CL2017001289A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462083031P 2014-11-21 2014-11-21

Publications (1)

Publication Number Publication Date
CL2017001289A1 true CL2017001289A1 (es) 2018-03-02

Family

ID=56014622

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001289A CL2017001289A1 (es) 2014-11-21 2017-05-19 Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).

Country Status (17)

Country Link
US (5) US10233187B2 (OSRAM)
EP (1) EP3221321B1 (OSRAM)
JP (3) JP7224102B2 (OSRAM)
KR (1) KR20170117020A (OSRAM)
CN (2) CN111662297A (OSRAM)
AU (2) AU2015349687B2 (OSRAM)
CA (1) CA2968434A1 (OSRAM)
CL (1) CL2017001289A1 (OSRAM)
CO (1) CO2017005784A2 (OSRAM)
ES (1) ES2911293T3 (OSRAM)
IL (1) IL252309B (OSRAM)
MX (1) MX370480B (OSRAM)
MY (1) MY192927A (OSRAM)
RU (1) RU2706007C2 (OSRAM)
SA (1) SA517381566B1 (OSRAM)
SG (2) SG11201703953WA (OSRAM)
WO (1) WO2016081918A1 (OSRAM)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
US12441704B2 (en) 2019-12-20 2025-10-14 Nuevolution A/S Compounds active towards nuclear receptors

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
MY194204A (en) 2014-08-04 2022-11-21 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
SG11201703953WA (en) * 2014-11-21 2017-06-29 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
HK1249756A1 (zh) * 2015-03-26 2018-11-09 Akarna Therapeutics, Ltd. 用於治疗疾病的稠合双环化合物
BR112018073460A2 (pt) * 2016-05-25 2019-07-09 Akarna Therapeutics Ltd terapias combinadas usando moduladores do receptor farnesoide x (fxr)
PT3730487T (pt) 2016-06-13 2022-07-22 Gilead Sciences Inc Derivados de azetidina como moduladores de fxr (nr1h4)
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
PL4122464T3 (pl) 2017-03-28 2024-09-16 Gilead Sciences, Inc. Kombinacje terapeutyczne do leczenia chorób wątroby
CN111542319A (zh) * 2017-06-02 2020-08-14 阿卡纳治疗学有限公司 稠合的双环化合物
EP3911647B1 (en) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
AU2020225225B2 (en) 2019-02-19 2022-12-22 Gilead Sciences, Inc. Solid forms of FXR agonists
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
JP2022541503A (ja) 2019-07-23 2022-09-26 ノバルティス アーゲー Ｆｘｒアゴニストを使用した肝疾患の組み合わせ処置
TW202114671A (zh) 2019-07-23 2021-04-16 瑞士商諾華公司 包含fxr促效劑之治療
JOP20220057A1 (ar) 2019-09-03 2023-01-30 Novartis Ag علاج أمراض أو اضطرابات الكبد تشتمل على مضادات مستقبل actrii
EP4031137A1 (en) 2019-09-19 2022-07-27 Novartis AG Treatment comprising fxr agonists
CN114502198A (zh) 2019-09-30 2022-05-13 诺华股份有限公司 包括使用fxr激动剂的治疗
TW202135811A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 使用整聯蛋白抑制劑組合治療肝臟疾病
UY39391A (es) * 2020-08-24 2022-03-31 Adama Makhteshim Ltd Proceso para la preparación de pirazoles sustituidos
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
US7402680B2 (en) 2003-09-17 2008-07-22 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2334681A1 (en) 2008-09-26 2011-06-22 Wyeth LLC 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
US8252826B2 (en) 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
SG11201703953WA (en) * 2014-11-21 2017-06-29 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
EP3463372A4 (en) * 2016-05-25 2019-11-13 Akarna Therapeutics, Ltd. CONDENSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
US12441704B2 (en) 2019-12-20 2025-10-14 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors

Also Published As

Publication number Publication date
EP3221321B1 (en) 2021-12-15
BR112017010627A2 (pt) 2018-02-14
JP7224102B2 (ja) 2023-02-17
US20190308977A1 (en) 2019-10-10
MX370480B (es) 2019-12-16
AU2015349687B2 (en) 2020-07-09
CN107207513A (zh) 2017-09-26
SG10202010386PA (en) 2020-11-27
IL252309A0 (en) 2017-07-31
IL252309B (en) 2021-01-31
KR20170117020A (ko) 2017-10-20
JP2017535614A (ja) 2017-11-30
US20230183247A1 (en) 2023-06-15
SG11201703953WA (en) 2017-06-29
AU2015349687A1 (en) 2017-06-29
MY192927A (en) 2022-09-15
US10233187B2 (en) 2019-03-19
JP2021011482A (ja) 2021-02-04
CN111662297A (zh) 2020-09-15
CA2968434A1 (en) 2016-05-26
CO2017005784A2 (es) 2017-10-31
EP3221321A1 (en) 2017-09-27
RU2017121588A (ru) 2018-12-24
AU2020250270A1 (en) 2020-11-05
SA517381566B1 (ar) 2021-05-16
EP3221321A4 (en) 2018-04-25
US20210147426A1 (en) 2021-05-20
US20170355699A1 (en) 2017-12-14
JP2023011731A (ja) 2023-01-24
ES2911293T3 (es) 2022-05-18
MX2017006694A (es) 2018-03-16
WO2016081918A1 (en) 2016-05-26
CN107207513B (zh) 2020-07-28
RU2706007C2 (ru) 2019-11-13
HK1244802A1 (zh) 2018-08-17
US20250171446A1 (en) 2025-05-29
AU2020250270B2 (en) 2022-08-25
RU2017121588A3 (OSRAM) 2019-05-21

Similar Documents

Publication Publication Date Title
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
CL2016001871A1 (es) Anticuerpos humanos para pd-1
MX387587B (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
AR101905A1 (es) Compuestos bicíclicos
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
MX389867B (es) Compuestos de pirazol como moduladores de fshr y usos de los mismos.
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2017002469A (es) Composiciones de matrices extracelulares.
MX2017008097A (es) Sintesis comercialmente viable de cantaridina y derivados bioactivos de cantaridina.
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX382864B (es) Formulaciones de anticuerpos cristalinos.
MX373197B (es) Formulaciones estables de undecanoato de testosterona.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
EA201691203A1 (ru) Твёрдые формы тенофовира
UY37009A (es) Formulaciones granuladas de giberelina
CO7051029A2 (es) Proceso para la preparacion de fenilpropanonas sustituidas